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Cutaneous T cell lymphoma is a clonally derived,
skin-invasive malignancy of CD4+ T lymphocytes
with the phenotype of mature helper T cells. Previous
work has demonstrated that the SeÂzary form, or
typically leukemic form of cutaneous T cell lym-
phoma, is characterized by prominent immunologic
defects, including depressed cell-mediated immunity
associated with marked defects in the production of
interleukin-12 and other type 1 helper T cell cyto-
kines. Recent clinical trials with recombinant human
interleukin-12 for cutaneous T cell lymphoma have
demonstrated that it is a potent therapeutic agent,
which induces cytotoxic T cell responses. Neverthe-
less, a high rate of refractoriness to recombinant
human interleukin-12 occurred in these studies that
may be related to the downmodulation of inter-
leukin-12 receptor expression by chronic interleukin-
12 use. In an effort to enhance the overall response
rate and to overcome the refractoriness to recombi-
nant human interleukin-12 therapy, we studied the
immunologic effects in vitro of adding interleukin-2
to interleukin-12 as a model to achieve these goals.
We examined the stimulation of interferon-g produc-
tion, natural killer cell activity and interleukin-12
receptor expression by T cells of cutaneous T cell
lymphoma patients. The addition of interleukin-12 to
cutaneous T cell lymphoma patient peripheral blood
cells resulted in the production of interferon-g
(mean = 7914 pg per ml 6 2161, n = 15) as did inter-
leukin-2 alone (mean = 7222 pg per ml 6 2228,
n = 15). Importantly, the addition of interleukin-2 to
the interleukin-12 synergistically enhanced the levels
of interferon-g produced (mean = 16 792 pg per
ml 6 2492 n = 15) (p < 0.01). Similarly, addition of
interleukin-2 to interleukin-12 synergistically
enhanced both the natural killer cell activity of 15
cutaneous T cell lymphoma patients as well as T cell
surface interleukin-12 receptor expression in com-
parison with the effects of interleukin-12 or interleu-
kin-2 alone. Thus, interleukin-2 plus interleukin-12
unequivocally produces the synergistic enhancement
of multiple parameters of cell-mediated immunity as
well as upmodulating interleukin-12 receptor expres-
sion; this indicates that protocols combining these
two potent immune enhancing cytokines may have
added therapeutic bene®t for cutaneous T cell lym-
phoma. Key words: CTCL T cell/IL-2/IL-12/IL-12
receptors. J Invest Dermatol 118:366±371, 2002
C
utaneous T cell lymphoma (CTCL) is a lymphopro-
liferative disorder typically characterized by invasion
of the skin with clonally derived malignant CD4+
lymphocytes that bear the phenotype of mature
helper T cells (Edelson, 1980; Haynes et al, 1981;
Weiss et al, 1985). SeÂzary syndrome is a more advanced stage of
CTCL. It usually presents with diffuse skin involvement, general-
ized lymphadenopathy, and the presence of circulating malignant
CD4+/CD45RO+ T cells (Haynes et al, 1981; Rook et al, 1997).
SeÂzary syndrome is also characterized by a variety of immunologic
abnormalities, including depressed cell-mediated cytotoxicity,
de®cient responsiveness of T cells to antigens and mitogens,
elevated serum IgE and IgA, as well as eosinophilia (Rook et al,
1993; Rook and Heald, 1995). Recent studies of the nature of the
malignant T cells have provided evidence that these cells are at least
partially responsible for the generation of the immune defects by
way of production of immunosuppressive T helper type (Th) 2
cytokines such as interleukin (IL)-4, IL-5, and IL-10, and depressed
Th1 type cytokines (Vowels et al, 1992, 1994; Rook and Heald,
1995; Rook et al, 1995; Dummer et al, 1996).
In contrast to increased Th2 cytokine production, we have also
observed a marked depression in production of Th1 cytokines, IL-2
and interferon (IFN)-g, by peripheral blood mononuclear cells
(PBMC) from SeÂzary syndrome patients (Vowels et al, 1992, 1994;
Rook et al, 1993). As Th1 cytokines are critical for the
development of normal cell-mediated immunity and are, therefore,
necessary for the genesis of anti-tumor immunity, this ®nding may
account for the progressive depression in cell-mediated immunity
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associated with the progression of clinical disease. Thus, in the
setting of depressed Th1 cytokine production and increased Th2
cytokines, which can suppress cell-mediated immunity (Rook et al,
1993), these observations help us to understand further the basis for
depressed cell-mediated immunity in advanced CTCL.
IL-12 is a monocyte/macrophage derived cytokine, which is a
powerful inducer of IFN-g production by T cells and natural killer
cells, and appears to be necessary for the differentiation of Th1 type
helper T cell responses (Robertson et al, 1992; Manetti et al, 1993).
Moreover, IL-12 plays an important part in the activation and
differentiation of cytotoxic T lymphocytes (CTL) (Gately et al,
1992). It is this latter activity that is an important aspect of the anti-
tumor immunity induced by IL-12 that has been demonstrated in
animals (Brunda et al, 1993). Previously our in vitro ®ndings among
patients with the SeÂzary form of CTCL indicated a profound
de®ciency in their ability to produce IL-12 (Rook et al, 1993). It is
also noteworthy that we demonstrated that recombinant IL-12
could normalize IFN-g production, enhance cell-mediated cyto-
toxicity and augment natural killer cell cytotoxicity when added to
PBMC from advanced CTCL patients (Rook et al, 1995). Previous
clinical trials with recombinant human IL-12 (rhIL-12) for CTCL
have demonstrated that it is a potent therapeutic agent, which
induces cytotoxic T cell responses; however, repeated administra-
tion of IL-12 induced a reversible suppression of IL-12-dependent
responses, such as IFN-g production, limiting the therapeutic
effectiveness of the treatment. Although, the underlying mechan-
ism of this refractoriness remains to be fully elucidated, observed
downmodulation of IL-12 receptor (IL-12R) expression and
increased degradation of STAT4 protein, a critical IL-12 signaling
factor, provided plausible explanation for IL-12 induced unrespon-
siveness (Rook et al, 1999; Wang et al, 2001). Furthermore, studies
of IL-12-treated rodents indicated that nitric oxide generated by
macrophages played an important part in the suppression of IL-12
responses (Koblish et al, 1998).
Different therapeutic regimens have been considered to improve
the effectiveness of IL-12 in cancer therapy, including the
combination of IL-12 with other biologic response modi®ers
such as IL-2. IL-2 is another potent Th1 type cytokine that is
known for its anti-tumor activity and its augmentatory effects on
cell-mediated immunity (Trinchieri et al, 1984). IL-2 has also been
shown to enhance the proliferation and cytotoxic function of
natural killer cells in vitro and in vivo (Henney et al, 1981; Trinchieri
et al, 1984; Caligiuri et al, 1993). Importantly, IL-2 production was
also found to be de®cient by PBMC of SeÂzary patients (Rook et al,
1993).
Although the combination of IL-12 and IL-2 has been associated
with some toxicity in animal models, the treatment of murine
tumors with IL-12 plus IL-2 was more effective than either of those
cytokines alone in inducing tumor regression (Wigginton et al,
1996). Recently, Wang et al (2000), have shown that IL-2 can
enhance the response of human natural killer cells to IL-12 through
upregulation of IL-12R and increased phosphorylation of STAT4.
These data suggest that combining IL-2 with IL-12 may result in
augmented anti-tumor activity in humans.
In this study, we have adopted the use of combined biologic
response modi®ers as a more potent therapeutic approach to
enhance the overall response rate of patients with CTCL and to
overcome the refractoriness to rhIL-12 therapy observed in
previous clinical trials. We studied the immunologic effects in vitro
of adding IL-2 to IL-12 as a model to achieve these goals. The
effect of these two potent cytokines on the stimulation of multiple
immunologic parameters, including IFN-g production, enhance-
ment of natural killer cell activity, and upregulation of IL-12R
expression by T cells of CTCL patients were examined.
MATERIALS AND METHODS
Patients participating in this study were diagnosed with SeÂzary syndrome
(Edelson, 1980), the leukemic form of CTCL, on the basis of clinical,
histopathologic, and immunohistologic criteria (Murphy, 1988).
Characterization of patient circulating malignant T cells was performed
by analysis of 1 mm sections of formalin-®xed peripheral blood buffy
coats by detection of mononuclear cells possessing cerebriform nuclear
morphology. In addition, ¯uorescence-activated cell sorting (FACS)
analysis was used to select speci®cally typical malignant clonal populations
that were CD4+/CD7± (Murphy, 1988). Using these two techniques,
three groups of patients with SeÂzary syndrome were studied. The group,
referred to as the high ``tumor burden'' group, consisted of four patients
with SeÂzary counts ranging from approximately 50% up to 99% of
mononuclear cells. The second group referred to as the intermediate
``tumor burden'' group consisted of ®ve patients with SeÂzary counts that
were approximately 20±50% of mononuclear cells, and the third group a
low ``tumor burden'' group consisted of six patients with SeÂzary counts
ranging from approximately 10 to 20% of mononuclear cells. None of
the patients were receiving cytotoxic drugs or systemic or topical
corticosteroids at the time of study. Samples from 13 healthy volunteers
served as controls. Donations of blood by patients (n = 15) or normal
volunteers (n = 15) in this study conformed to IRB-approved protocol
and informed consents were obtained.
Cytokines, antibodies, and reagents Mouse IgG1 antibodies against
human IL-12R b2 chains were a generous gift from Dr Kathy Wang
and Dr Jerome Ritz (Dana-Farber Cancer Institute, Boston, MA).
Phycoerythrin-labeled goat anti-mouse antibodies were purchased from
Jackson Immuno-Research Laboratories, Inc. (Jennersville, PA). Mouse
IgG1 isotype control, rat IgG and goat serum blocking reagents were
purchased from Sigma (St Louis, MO). Fluorescein isothiocyanate- and
peridinin chlorophyll protein (PerCP)-labeled antibodies for CD4+ and
CD8+ cells were purchased from Pharmingen (San Diego, CA) and
Becton Dickinson (San Jose, CA), respectively. rIL-12 was provided by
Dr Stanley Wolf of the Genetics Institute (Andover, MA) and rhIL-2
was purchased from Boehringer Mannheim (Indianapolis, IN)
PBMC preparation and culture criteria PBMC were prepared as
described previously (Rook et al, 1995). Brie¯y, venous blood was
collected into heparinized syringes using uniform standards for both
SeÂzary syndrome patients and normal volunteers. The blood was then
diluted 2-fold with Dulbecco's phosphate-buffered saline (BioWhittaker,
Walkersville, MD), pH 7.2, layered over Ficoll-Hypaque (Amersham,
Uppsala, Sweden), and centrifuged at 500 3 g for 30 min at room
temperature. The interface containing the mononuclear cell fraction was
collected and cells were washed three times with phosphate-buffered
saline. Cells were used immediately after puri®cation.
Cell cultures were set up at a ®nal concentration of 1 3 106 cells per
ml in RPMI 1640 media (GIBCO-BRL, Grand Island, NY) supple-
mented with 10% heat-inactivated fetal bovine serum, 200 mM per l L-
glutamine, and 100 U penicillin-streptomycin per ml for 70 h. Certain
cultures were supplemented with the mitogen phytohemagglutinin
(PHA) (1 mg per ml or 2 mg per ml), predetermined concentrations of
cytokines (IL-12: 1 ng per ml; and IL-2: 100 U per ml).
Cell surface staining and ¯ow cytometric analysis of IL-12R b2
subunits on T subset CD4+ and CD8+ cells Analysis of the
expression of IL-12R b2 subunits on CD4+ and CD8+ cells was
accomplished using ¯ow cytometric analysis. Approximately 106 PBMC
per sample were harvested from different cell cultures and washed twice
with washing solution (1 3 phosphate-buffered saline, 3% fetal bovine
serum, pH 7.4). Cells were then incubated with Rat IgG (Sigma) for
10 min on ice to reduce nonspeci®c binding. Mouse IgG1 against IL-
12R b2 (Dana-Farber Cancer Institute, Boston, MA) subunit at
concentrations of 10 ml of 1:1000 dilution of acetic ¯uid per 50 ml
phosphate-buffered saline containing 3% fetal bovine serum, was then
added to the cells and incubated at 4°C for 30 min. Puri®ed mouse
IgG1 (Sigma) at the same concentration was used as an appropriate
control antibody. Cells were subsequently washed twice with washing
media and incubated with 20 ml goat serum (Sigma) on ice for 10 min
to block nonspeci®c binding. Finally phycoerythrin-labeled goat anti-
mouse IgG1 secondary antibody (BioSource International, Camarillo,
CA) was added at a concentration of 1:50 dilution.
To differentiate the expression of IL-12R b2 on CD4+ and CD8+
subpopulation, cells were stained with ¯uorescein isothiocyanate-labeled
anti-CD4 (Pharmingen) and PerCP-labeled anti-CD8 (Becton
Dickinson) antibodies. Fluorescein isothiocyanate-and PerCP-labeled
mouse IgG were used as controls, respectively. After washing, stained
cells were directly analyzed on a FACScan ¯ow cytometer (Becton
Dickinson). Data were processed by using the CELLQuest program
(Becton Dickinson). Typically 10,000 cells in each sample were analyzed.
The level of IL-12R b2 subunit expression was measured by gating on
CD4+ or CD8+ cells and was expressed as percentage positive cells
expressing the IL-12R b2.
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Cytokine assays IFN-g was assayed by colorimetric enzyme-linked
immunosorbent assay (R&D Systems, Minneapolis, MN) according to
the manufacturer's speci®cations as previously described (Rook et al,
1995).
Natural killer cell function PBL were separated from heparinized
whole blood by Ficoll-Hypaque gradient centrifugation. Cells were
washed three times and were resuspended in RPMI 1640 medium (Life
Technologies, Inc., Gaithersburg, MD) supplemented with 10% fetal
bovine serum. Target cells that were used in assays for natural killer cell
function were prepared from suspension cultures of the K562 line. The
assay was performed as previously published (Rook et al, 1995).
Statistical analysis The data on IFN-g production were analyzed
using an unpaired, two-tailed Student's t test or the Wilcoxon ranked
sum test for paired groups to determine the statistical signi®cance of the
data, and p < 0.05 was considered signi®cant.
RESULTS
IL-12 plus IL-2 synergistically enhance the production of
IFN-g by PBMC from SeÂzary syndrome patients Previous
studies have demonstrated that recombinant IL-12 can enhance
IFN-g production by the PBMC of patients with SeÂzary syndrome
(Rook et al, 1995). Nevertheless, during treatment of patients with
IL-12, refractoriness to this biologic effect frequently occurs in
association with clinical refractoriness to IL-12 (Gollob et al, 1998;
Rook et al, 1999). As a model for overcoming the refractory state,
we examined the immunologic effects of adding IL-2 to IL-12.
IFN-g production was examined using the PBMC of 15 patients
with SeÂzary syndrome with varying burdens of circulating
malignant T cells as described in Materials and Methods, and
PBMC from 15 healthy sex- and age-matched volunteers as
controls. Mononuclear cells were cultured with either 1 ng IL-12
per ml or 100 units of IL-2 per ml or both with 1 mg PHA per ml
for 48 h. Supernatants were assayed for IFN-g levels by enzyme-
linked immunosorbent assay. As shown in Fig 1, IL-12 induced
substantial IFN-g production by the patients' PBMC (mean 6 SE
7914 pg per ml 6 2161) as did IL-2 alone (mean 7222 pg per
Figure 1. Synergistic effect of IL-12 plus IL-2 on IFN-g
production by PBMC from SeÂzary syndrome patients. PBMC
stimulated with PHA were cultured with either IL-12, IL-2, or IL-12
plus IL-2 for 70 h. Supernatants were assayed for the presence of IFN-g
by enzyme-linked immunosorbent assay. Light gray bars represent values
for normal volunteers, whereas dark gray bars represent values for SeÂzary
syndrome patients.
Figure 2. IL-12 plus IL-2 increase the expression of IL-12R b2 on T cells from normal volunteers. PBMC from normal volunteers were
cultured in the presence of PHA and either IL-12, IL-2, or IL-12 plus IL-2 for 70 h. Analysis was performed by ¯ow cytometry after gating on CD4+
and CD8+ T cells. Data represent percentage of cells expressing IL-12R b2. A representative experiment is shown using the PBMC of a normal
volunteer.
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ml 6 2228). It is noteworthy that addition of IL-2 to IL-12
markedly enhanced the IFN-g produced by the PBMC of all
patients studied in comparison with IL-12 or IL-2 alone (mean
16790 pg per ml 6 2490) (p < 0.01).
Addition of IL-2 to IL-12 markedly upmodulates the IL-12R
b2 expression on T cells of SeÂzary syndrome patients The
IL-12R b2 is the signaling receptor through which IL-12
transduces its signal to IL-12 responsive genes (Presky et al,
1996). Therefore, in an effort to understand the potential
synergistic effects of adding IL-2 to IL-12, the ability of these
cytokines to modulate IL-12R b2 expression on T cells of SeÂzary
syndrome patients was examined. Freshly isolated T cells from
SeÂzary syndrome patients and age- and sex-matched normal
volunteers were cultured with either a suboptimal dose of PHA
alone (1±2 mg per ml) or with combinations of 1 ng IL-12 per ml,
100 units of IL-2 per ml, or both with PHA for 70 h followed by
¯ow cytometric analysis. IL-12 plus IL-2 induced more expression
of IL-12R b2 on CD4+ and CD8+ T cells from healthy controls in
comparison with IL-12 alone. A representative individual
experiment is shown in Fig 2. T cells from three groups of
patients with SeÂzary syndrome were also studied for the modulatory
effects of IL-2 added to IL-12. These groups included those with
high, intermediate, or low circulating tumor burden as described in
Materials and Methods. PBMC from patients with a low circulating
burden of malignant T cells demonstrated a marked enhancement
of IL-12R b2 expression when cells were cultured with IL-2 plus
IL-12 in comparison with IL-12 alone (Fig 3). For example, after
culture of one SeÂzary patient's PBMC with IL-2 plus IL-12, 88% of
CD4+ T cells and 31% of CD8+ T cells expressed IL-12R b2 as
compared with only 27% of CD4+ T cells and 13% of CD8+ T cells
after culture with IL-12 alone (Fig 3). In contrast to results with
low tumor burden patients, those with an intermediate and high
burden of circulating malignant T cells demonstrated progressively
diminished responses of IL-12R b2 expression when their PBMC
were cultured with IL-12 alone or with IL-2 in addition to IL-12
(Fig 4).
The functional consequences of adding IL-2 to IL-12:
Enhanced natural killer cell activity of SeÂzary syndrome
patients Although IL-2 plus IL-12 appear to enhance the
production of IFN-g by the cells of all patients with SeÂzary
syndrome and to upmodulate the expression of IL-12R b2 on the
PBMC of many patients, the functional consequences of these
cytokines to increase cell-mediated immunity may be most
clinically relevant. Therefore, one measure of cell-mediated
immunity that we chose to study was the modulation of natural
killer cell activity. The PBMC of 15 patients with SeÂzary syndrome
were cultured with either medium alone, 1 ng IL-12 per ml, 100
units IL-2 per ml or both cytokines for 24 h followed by a Cr51
release assay using K562 cells as target cells as previously described
(Rook et al, 1995). As shown in Fig 5, signi®cant augmentation of
natural killer cell activity occurred with either IL-12 (p < 0.5) or
IL-2 (p < 0.0015) alone in comparison with medium and the mean
natural killer cell activity of the 15 patients was further boosted by
combining IL-12 with IL-2 (p < 0.0001). It is noteworthy that
even some patients with very high levels of circulating malignant T
cells experienced signi®cant additional augmentation of natural
killer cell activity when their PBMC were cultured with IL-12 plus
IL-2 in comparison with either cytokine alone or to medium alone.
An example of this effect is shown in Fig 6 where an experiment
was performed using the PBMC of a patient who had 90% of their
circulating mononuclear cells identi®ed as SeÂzary cells by
morphologic and by ¯ow cytometric criteria.
Figure 3. IL-12 plus IL-2 increase the expression of IL-12R b2 on CD4+ and CD8+ T cells of low tumor burden SeÂzary syndrome
patients. PBMC from a SeÂzary syndrome patient with a low circulating tumor burden were cultured in the presence of PHA and were stimulated
with IL-12, IL-2, or both for 70 h. Analysis was done by ¯ow cytometry after gating on CD4+ or CD8+ T cells. Similar results were obtained using
the cells of ®ve more patients with a low burden of circulating malignant T cells.
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DISCUSSION
Two previous clinical trials using recombinant IL-12 to treat
CTCL indicated that this cytokine is biologically active for this
disorder with the demonstration of approximately a 50% response
rate characterized by signi®cant clearing of skin lesions (Rook et al,
1999; Gollob et al, 2000). Nevertheless, clinical refractoriness, as
evidenced by the early relapse of patients who had experienced a
complete response or by the early plateau of a partial response, was
not an infrequent observation during both clinical trials. Our
preliminary ®ndings have related this clinical phenomenon to
decreased IFN-g production and to the downmodulation of IL-
12R b2 expression (AH Rook et al, unpublished observations).
Similarly, Gollob et al (2000) observed a clinical phenotype among
IL-12 responsive solid tumor patients that correlated with the
persistent induction of IFN-g, IL-15, and IL-18 following the long-
Figure 4. IL-12 plus IL-2 fails to upregulate the expression of IL-12R b2 on T cells of SeÂzary syndrome patients with a high circulating
burden of malignant T cells. PBMC from a SeÂzary syndrome patient with a high circulating tumor burden were cultured in the presence of PHA
and were stimulated with IL-12, IL-2, or both for 70 h. Analysis was done by ¯ow cytometry after gating on CD4+ or CD8+ T cells. Similar results
were obtained using the cells of three more patients with a high burden of circulating malignant T cells.
Figure 5. IL-12 plus IL-2 augment natural killer cell activity of
SeÂzary syndrome patients. PBMC from patients with SeÂzary
syndrome (n = 15) were cultured for 24 h with either medium, IL-12,
IL-2, or IL-12 plus IL-2 followed by a 4 h Cr51 release assay using K562
cells as targets. The effector to target ratio shown is 25:1.
Figure 6. IL-12 plus IL-2 augments natural killer cell activity of a
SeÂzary syndrome patient with a high burden of circulating
malignant T cells. PBMC from a patient with 90% circulating
malignant T cells were cultured for 24 h with either medium alone, IL-12
alone, IL-2 alone, or IL-2 plus IL-12 followed by a 4 h Cr51 release assay
using K562 cells as targets. The effector to target ratio shown is 25:1.
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term administration of IL-12. Conversely, patients who were
clinically unresponsive to IL-12 exhibited a rapidly diminished
capacity to produce IFN-g and IL-15 during IL-12 administration.
Thus, in an effort to overcome the clinical and biologic
refractoriness to IL-12 and to enhance the clinical bene®t of IL-
12 treatment for CTCL patients, we postulated that addition of
another IFN-g inducing cytokine to IL-12 could potentially have
salutary therapeutic effects.
Because IL-2 is known to induce potently IFN-g production
independently of IL-12, it was a logical choice of cytokines to
combine with IL-12 (Chan et al, 1991). The results of our study
clearly establish that combining IL-2 with IL-12 leads to the
synergistic enhancement of IFN-g production by PBMC derived
from patients with SeÂzary syndrome. In fact, regardless of the
circulating burden of malignant T cells, the PBMC of all patients
studied manifested this immune potentiating effect of combining
IL-2 with IL-12. Thus, it is anticipated that adding IL-2 to rIL-12
therapy might at least partially prevent the attenuation of IFN-g
production that occurs during the chronic use of rhIL-12.
Previous studies have identi®ed IFN-g as a potent upmodulatory
cytokine for expression of the IL-12R b2 (Zaki et al, 2001). In
these studies, IFN-g appeared to induce the most signi®cant
expression of IL-12R b2 on the T cells of SeÂzary syndrome patients
in comparison with IFN-a, IL-18, and IL-12 itself (Zaki et al,
2001). Furthermore, patients who had a more modest circulating
burden of tumor cells had T cells that were more responsive to
IFN-g in regard to IL-12R expression in comparison with patients
with a high circulating tumor burden. The results of this study are
consistent with these previous ®ndings in that patients with a more
modest circulating tumor burden exhibited a more pronounced
augmentation of IL-12R b2 expression in response to IL-12 and
IL-2 in comparison with patients with a high circulating tumor
burden. It remains to be established what the underlying mech-
anisms are that are responsible for the low IL-12R b2 expression on
the T cells of these patients and to what extent the signaling
pathways in their remaining normal T cells are impaired. Our
®ndings demonstrate a discrepancy between the levels of IL-12R
b2 expression on the T cells of heavy tumor burden patients and
the ability of their cells to produce increased levels of IFN-g in
response to IL-12 plus IL-2.
Although the effects of combined IL-12 plus IL-2 on IL-12R b2
on natural killer cells of CTCL patients have not been examined in
recent studies, Wang et al (2000) recently reported that the
combination of these cytokines elevated the expression of IL-12R
on natural killer cells and enhanced IL-12 signaling in natural killer
cells. It is therefore possible that natural killer cells from our patients,
including those derived from heavy tumor burden patients were
important participants in the IFN-g production process. Moreover,
these results with natural killer cell enhancement indicate that
individual patients with advanced disease can respond with
synergistic increases in natural killer cell activity. Two patients
with more than 90% circulating malignant T cells who demonstrated
such an enhancement of natural killer cell activity in response to IL-2
plus IL-12 were an excellent example of this phenomenon. As
natural killer cell activity may be an excellent surrogate marker for
the functional establishment of cytolytic T lymphocyte activity, our
®ndings are clearly relevant to the generation of host anti-tumor
activity. The importance of cytolytic T lymphocytes in CTCL has
been supported by the ®ndings of Hoppe et al (1995), demonstrating
a correlation between the presence of CD8+ tumor in®ltrating
lymphocytes in skin lesions and favorable prognosis among patients.
Furthermore, our observations among IL-12-treated CTCL patients
indicate that IL-12 potently induces cytolytic T lymphocyte
in®ltrates within regressing skin lesions (Rook et al, 1999). Our
preliminary studies demonstrate the capacity of these in®ltrating
CD8+ T cells to mediate apoptosis of the CD4+ malignant T cells
(LE French and AH Rook, unpublished observations). Thus, the
results of this study provide reason to be optimistic regarding a future
therapeutic approach utilizing IL-2 plus rhIL-12 for patients with
cutaneous T cell lymphoma.
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